Legend Biotech (LEGN) Enterprise Value (2020 - 2026)

Legend Biotech (LEGN) has 8 years of Enterprise Value data on file, last reported at -$646.4 million in Q1 2026.

• Quarterly Enterprise Value rose 35.72% year-over-year to -$646.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$646.4 million (up 35.72% YoY) and the FY2025 annual result came in at -$901.9 million, down 214.5% from the prior year.
• Enterprise Value rose to -$646.4 million in Q1 2026, from -$901.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$266.7 million in Q2 2025 to a low of -$1.5 billion in Q2 2023.
• A 5-year average of -$868.1 million and a median of -$901.9 million in 2025 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value surged 77.57% — and 2025, when it tumbled 214.5%.
• Tracing LEGN's Enterprise Value over 5 years: stood at -$971.6 million in 2022, then sank by 31.57% to -$1.3 billion in 2023, then surged by 77.57% to -$286.8 million in 2024, then plunged by 214.5% to -$901.9 million in 2025, then grew by 28.33% to -$646.4 million in 2026.
• The last three Enterprise Value figures came in at -$646.4 million (Q1 2026), -$901.9 million (Q4 2025), and -$278.9 million (Q3 2025), per Business Quant data.